The Priority Review

Tag

Stream

353 stories · page 13 of 30

Stories

  1. Clinical trials

    Hoffmann-La Roche posts results of Phase III crovalimab study in aHUS

    Results for the Phase III, single-arm study of crovalimab in adult and adolescent patients with atypical hemolytic uremic syndrome were first posted on ClinicalTrials.gov on October 30, 2026, after enrolling 83 participants. The study, which began on October 22, 2021, reached primary completion on October 9, 2025.

  2. Regulation

    PRAC starts review of Deanxit and human normal immunoglobulin safety signal

    PRAC has begun a review of Deanxit, a fixed-dose combination for depression and anxiety, after reports of serious neurological and psychiatric side effects. PRAC also started a review of a safety signal concerning increased reporting of hypersensitivity reactions associated with specific batches of human normal immunoglobulin medicines, including Flebogamma DIF, Yimmugo and Gamunex that have been withdrawn.

  3. Regulation

    FDA releases revised draft guidance on drug delivery device performance

    The FDA announced the availability of a revised draft guidance published October 30, 2026. The guidance replaces the draft guidance announced July 1, 2024 and provides recommendations for development and organization of device drug-delivery performance information.

  4. Regulation

    FDA classifies radiology software for fibrotic lung disease as class II

    The FDA finalized an order classifying the radiology software for referral of findings related to fibrotic lung disease as class II with special controls that will be part of the codified language for classification. The agency said the classification provides reasonable assurance of safety and effectiveness and may enhance patients' access to beneficial innovative devices by reducing regulatory burdens.

  5. Clinical trials

    PROSpect trial finds no difference in ventilator-free days with prone positioning or HFOV

    The PROSpect phase 3 trial, enrolling 424 of 600 planned patients, found no significant difference in ventilator-free days between prone and supine positioning (median 17·9 vs 17·4 days) or between HFOV and conventional ventilation (17·3 vs 18·0 days). The authors reported more frequent airway obstruction and immobility-related pressure injuries with prone positioning and more haemodynamic instability with HFOV, concluding that routine use of these strategies is not recommended.

  6. Policy

    BioMarin enters exclusive worldwide license for investigational Fabry therapy

    BioMarin will make an upfront payment of $70 million for HM15421/GC1134A and may receive up to $405 million in milestone payments. The company will assume sole responsibility for all subsequent clinical development, manufacturing and commercialization outside of Korea.

  7. Clinical trials

    Abbott initiates CROWN-MV pivotal trial for Cephea device

    Abbott has started the CROWN-MV study, a prospective pivotal trial that will enroll up to 585 patients with symptomatic mitral valve disease in the U.S., Canada and Europe. The trial will evaluate the safety and effectiveness of the investigational Cephea Mitral Valve System, a catheter-based replacement option for patients not candidates for surgery or transcatheter repair.

  8. Policy

    Novavax earns $125 million milestone as Sanofi launches Phase 3 flu-COVID combo trial in Europe

    The payment was triggered when the fifth patient was dosed on Oct. 29, 2026. The study evaluates safety and immunogenicity of Nuvaxovid combined with Sanofi's Efluelda/Fluzone High-Dose vaccine in adults 60 and older.

  9. Clinical trials

    Jade Biosciences registers Phase 3 study of JADE101 in IgA nephropathy

    The study, titled the EVERGREEN STUDY, plans to enroll 480 participants and has a planned start date of December 2026. It will evaluate the safety and efficacy of JADE101 versus placebo in adults with immunoglobulin A nephropathy.

  10. Clinical trials

    Janssen registers Ramantamig and Daratumumab versus DVRd trial in newly diagnosed multiple myeloma

    The study, led by Janssen Research & Development, LLC, plans to enroll 1000 participants and is scheduled to start on December 14, 2026. It compares Ramantamig plus Daratumumab with the standard DVRd regimen followed by high-dose therapy, autologous stem cell transplant, and maintenance therapy.

  11. Clinical trials

    Jiangsu Simcere registers Phase II/III trial of SIM0811 in acute ischemic stroke

    Planned enrollment is 1092 participants and the study is expected to start on November 30, 2026, with primary completion projected for June 30, 2029. Researchers will compare different doses of SIM0811 to a placebo in patients treated within 4.5 to 24 hours after last known well.

  12. Clinical trials

    Alexion posts results of Phase 3 ARTEMIS ravulizumab trial

    The company posted results for its Phase 3 ARTEMIS study, which enrolled 555 participants and was terminated after primary completion on October 7, 2025. The trial assessed a single dose of ravulizumab IV versus placebo in adult participants with CKD undergoing non-emergent cardiac surgery with cardiopulmonary bypass.